Location : Home > Products > Inhibitors of Meditech > DNA Damage
Name:JIB-04
| Chemical structure | Code NO. |
MT0718 |
 |
Name |
JIB-04 |
Synonym |
JIB04; JIB 04 | |
CAS NO. |
199596-05-9 | |
Chemical Formula |
C17H13ClN4 | |
MW |
308.76 | |
Purity |
>98% | |
Solubility(R.T.: 25℃) |
DMSO 11.2 mg/mL; Water <1 mg/mL | |
Stability |
- 20℃, 2 years |
Availability and price
JIB-04 is in stock. Bulk available at low price, welcom to inquire quotation.
We offer big discount for bulk quantities. If you have any other questions or needs, please send email to sales@meditechbs.com. We’ll reply you asap.
Description
JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
IC50 Value: 230 nM (for JARID1A); 340 nM (for JMJD2E); 855 nM (for JMJD3) 445 nM (for JMJD2A); 435 nM (for JMJD2B); 1100 nM (for JMJD2C); 290 nM (for JMJD2D) [1]
Target: Jumonji Histone Demethylase
in vitro: JIB-04 induces transcriptional changes in a cancer-selective manner, including the downregulation of proliferative genes and the upregulation of the anti-proliferative/pro-apoptotic genes. JIB-04 blocks growth of lung and prostate cancer lines with IC50 as low as 10 nM, while produces less anti-proliferative activities on HBECs and PrSCs/PrECs [1].
in vivo: In two separate xenograft mouse models (H358 or A549), JIB-04 diminishes tumor growth, lowers Jumonji histone demethylase activity in tumors, and prolongs cancer survival [1].
IC50 Value: 230 nM (for JARID1A); 340 nM (for JMJD2E); 855 nM (for JMJD3) 445 nM (for JMJD2A); 435 nM (for JMJD2B); 1100 nM (for JMJD2C); 290 nM (for JMJD2D) [1]
Target: Jumonji Histone Demethylase
in vitro: JIB-04 induces transcriptional changes in a cancer-selective manner, including the downregulation of proliferative genes and the upregulation of the anti-proliferative/pro-apoptotic genes. JIB-04 blocks growth of lung and prostate cancer lines with IC50 as low as 10 nM, while produces less anti-proliferative activities on HBECs and PrSCs/PrECs [1].
in vivo: In two separate xenograft mouse models (H358 or A549), JIB-04 diminishes tumor growth, lowers Jumonji histone demethylase activity in tumors, and prolongs cancer survival [1].
References
Attention
Sold for research purposes only; not for human use of any kind.
